Neuphoria Therapeutics Inc. — Operating Income by Fiscal Year
3 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d28da42b-2b14-46d6-95bd-79434a0e6de9/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-1.1M | 2024-07-01 – 2025-06-30 | evidence 0001193125-25-223338 |
| FY 2024 | $-17.9M | 2023-07-01 – 2024-06-30 | evidence 0001213900-24-082909 |
| FY 2023 | $-22.0M | 2022-07-01 – 2023-06-30 | evidence 0001213900-24-082909 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).